Publication: 3382

A Phase I Trial Adding Poly(ADP-ribose) Polymerase Inhibitor Veliparib to Induction Carboplatin-Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Alliance A091101
      QxMD      Google Scholar   
Citation:
Oral Oncol vol 114 105171
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
10
Parents:
2900  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
Abbvie  
Grants:
U10CA180821, U10CA180882, UG1CA233327  
Corr. Author:
 
Authors:
                 
Networks:
CA824, IL043, LAPS-IL057, LAPS-MD017, LAPS-MN026, OH029   
Study
Alliance-A091101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords:
Head and neck squamous cell carcinoma, induction therapy, veliparib, PARP inhibition